What Is BPC-157 and Why Does Dosage Math Matter?
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a naturally occurring protein in human gastric juice. It has become one of the most actively studied compounds in regenerative peptide research, with animal models demonstrating accelerated repair across tendons, ligaments, muscle tissue, and the gastrointestinal tract. Researchers searching for a BPC-157 dosage calculator PDF are typically trying to solve one specific problem: translating a weight-based mcg/kg protocol into a precise syringe volume without making a unit-conversion mistake.
The challenge is that BPC-157 dosing involves three moving variables β vial size, reconstitution volume, and subject weight β and a static PDF can only handle predetermined scenarios. This guide walks through the complete calculation framework, explains the underlying research protocols, and shows you exactly how the math works at each step.
Research Use Only: BPC-157 is not approved by the FDA or any major regulatory authority for human use. All dosing information below reflects commonly referenced research protocols drawn from published preclinical literature and is provided for laboratory research reference only. This is not medical advice.---
BPC-157 Mechanism of Action: Why Dosing Precision Matters
Understanding BPC-157's mechanism clarifies why researchers care so much about dose accuracy. The peptide operates through several converging pathways:
- Angiogenesis: BPC-157 upregulates VEGF (vascular endothelial growth factor) and stimulates new capillary formation at injury sites, restoring nutrient and oxygen delivery to damaged tissue.
- Growth factor modulation: It also elevates FGF (fibroblast growth factor), which drives fibroblast proliferation β critical for tendon and ligament repair.
- Anti-inflammatory signaling: The peptide suppresses pro-inflammatory cytokines including TNF-Ξ±, reducing local inflammation without broad immunosuppression.
- Nitric oxide pathway: BPC-157 modulates nitric oxide synthase activity, contributing to vasodilation and improved microcirculation β particularly relevant for GI tract healing models.
In animal studies, these effects are dose-dependent within a relatively narrow therapeutic window. Too little and signaling is subthreshold; too much doesn't appear to proportionally increase benefit in most models. This is exactly why a reliable BPC-157 dosage calculator β rather than a rough estimate β is the standard starting point for any structured research protocol.
BPC-157 Dosage Calculator PDF: The Core Formula
Most downloadable BPC-157 dosage calculator PDFs present a two-step calculation. Here's how it works β and where static PDFs fall short.
Step 1: Calculate Total Daily Dose (mcg)
The most commonly referenced research protocol is weight-based: 5β10 mcg per kilogram of body weight per day. This range is drawn from rodent and rat studies extrapolated using standard interspecies scaling.
| Body Weight | Low End (5 mcg/kg) | High End (10 mcg/kg) |
|---|---|---|
| 60 kg (132 lb) | 300 mcg/day | 600 mcg/day |
| 70 kg (154 lb) | 350 mcg/day | 700 mcg/day |
| 80 kg (176 lb) | 400 mcg/day | 800 mcg/day |
| 90 kg (198 lb) | 450 mcg/day | 900 mcg/day |
| 100 kg (220 lb) | 500 mcg/day | 1,000 mcg/day |
Step 2: Convert Dose to Syringe Volume
This is where errors happen. The syringe volume you draw depends entirely on your reconstitution ratio. Use our peptide calculator to run this dynamically β but here's the manual formula:
Volume (mL) = Desired Dose (mcg) Γ· Concentration (mcg/mL)
Example: 5 mg vial + 2 mL bacteriostatic water = 2,500 mcg/mL concentration
- 250 mcg dose β 250 Γ· 2,500 = 0.10 mL (10 units on U-100 syringe)
- 500 mcg dose β 500 Γ· 2,500 = 0.20 mL (20 units on U-100 syringe)
- 700 mcg dose β 700 Γ· 2,500 = 0.28 mL (28 units on U-100 syringe)
A static PDF can only tabulate these values for one reconstitution ratio at a time. If you add 1 mL instead of 2 mL β which doubles the concentration to 5,000 mcg/mL β every value in that PDF is wrong. This is the core limitation of the PDF format for this application. The Capital Peptides dosage calculator adjusts in real time based on your actual vial size and diluent volume.
---Reconstitution Protocol for BPC-157 Research
Proper reconstitution is non-negotiable for research accuracy. BPC-157 is supplied as a lyophilized (freeze-dried) powder, typically in 5 mg or 10 mg vials. Bacteriostatic water (0.9% benzyl alcohol) is the standard diluent β it extends shelf life post-reconstitution compared to sterile water.
Standard Reconstitution Steps
- Allow the sealed vial to reach room temperature before opening.
- Wipe the rubber septum with an alcohol swab and allow to dry.
- Draw the desired volume of bacteriostatic water into a clean syringe.
- Inject the diluent slowly down the side of the vial β not directly onto the powder cake.
- Gently swirl (do not shake vigorously) until the powder is fully dissolved. The solution should be clear and colorless.
- Label with date and store at 2β8Β°C (36β46Β°F). Use reconstituted solution within 7β10 days.
Concentration Reference Table
| Vial Size | Bacteriostatic Water Added | Resulting Concentration |
|---|---|---|
| 5 mg | 1 mL | 5,000 mcg/mL |
| 5 mg | 2 mL | 2,500 mcg/mL |
| 5 mg | 5 mL | 1,000 mcg/mL |
| 10 mg | 2 mL | 5,000 mcg/mL |
| 10 mg | 4 mL | 2,500 mcg/mL |
Commonly Referenced BPC-157 Research Protocols
Published animal studies have used a range of administration routes. The following summarizes what appears most frequently in the peer-reviewed literature:
Subcutaneous Administration
The most common route in rodent models. Injections are administered once or twice daily, often near the injury site, at doses of 10 mcg/kg. In a 2015 study by Sikiric et al., subcutaneous BPC-157 at 10 mcg/kg significantly accelerated Achilles tendon transection healing in rats compared to controls.
Oral / Intragastric Administration
Multiple studies have examined oral BPC-157 in GI tract models. Notably, BPC-157 demonstrates unusual stability in gastric acid β a property attributed to its origin as a gastric protein fragment. Oral doses in research typically range from 10β100 mcg/kg in rodent models, though systemic bioavailability compared to subcutaneous delivery remains an open research question.
Protocol Duration
Most published studies run 7β28 days for acute injury models; chronic studies extend to 8β12 weeks. There is no established long-term safety data in primates or humans.
---BPC-157 Stacks in Research Contexts
Two peptide combinations appear frequently in the research literature and in protocol design discussions:
BPC-157 + TB-500 ("Wolverine Stack")
TB-500 (Thymosin Beta-4) operates systemically β mobilizing stem cells and promoting actin polymerization throughout the body. BPC-157's effects are more localized and tissue-specific. The combination is hypothesized to produce complementary healing coverage: systemic mobilization via TB-500 with targeted tissue repair via BPC-157. Use the peptide calculator to work out volumes when running multiple compounds in the same protocol.
BPC-157 + GHK-Cu
GHK-Cu (copper peptide) promotes collagen synthesis and has anti-inflammatory properties. Some researchers combine it with BPC-157 in skin and connective tissue studies, though combination data is limited to in vitro work.
---BPC-157 vs. TB-500: Key Research Differences
| Parameter | BPC-157 | TB-500 |
|---|---|---|
| Origin | Gastric protein fragment (human) | Thymosin beta-4 fragment (bovine) |
| Primary mechanism | VEGF, FGF, NO modulation | Actin binding, stem cell mobilization |
| Action radius | Localized / site-specific | Systemic |
| GI research data | Extensive | Limited |
| Typical research dose | 5β10 mcg/kg/day | 2β4 mg/week (loading), 1β2 mg/week (maintenance) |
| WADA status | Prohibited (S0) | Prohibited (S0) |
Safety Profile and Reported Side Effects
In the published animal literature, BPC-157 has a consistently favorable tolerability profile at research doses. No LD50 has been established in rodent models even at very high doses, and chronic administration studies have not produced organ toxicity signals. However, this should not be extrapolated to human safety β there are no completed Phase I or Phase II human clinical trials as of 2026.
Anecdotally reported effects in non-peer-reviewed contexts include:
- Injection site redness or mild discomfort
- Transient nausea with oral administration
- Fatigue in some reports (mechanism unclear)
As of early 2026, BPC-157 remains unclassified as a Schedule I or II substance in the United States but is not approved for compounding or prescription use β though regulatory discussions about compounding pathways are ongoing. It is prohibited under WADA's S0 category (non-approved substances) for competitive athletes.
---Storage Guidelines for Reconstituted BPC-157
- Unreconstituted powder: Stable at room temperature; refrigeration preferred for long-term storage.
- Reconstituted solution: Refrigerate at 2β8Β°C. Use within 7β10 days. Bacteriostatic water extends this window compared to plain sterile water.
- Do not freeze reconstituted peptide solutions β freeze-thaw cycles degrade the peptide structure.
- Protect from light; store in original amber vials where possible.
Why a Static PDF Falls Short β Use a Dynamic Calculator Instead
A downloadable BPC-157 dosage calculator PDF is a snapshot. It assumes fixed vial sizes and fixed reconstitution volumes, and it can't account for the variability that actual research protocols introduce. Common failure points include:
- Researcher uses a different reconstitution volume than the PDF assumes β wrong concentration β wrong draw volume
- PDF uses mg where researcher is thinking mcg β 1,000Γ error potential
- No accommodation for twice-daily split dosing vs. once-daily
- No adjustment for body weight outside common reference ranges
The Capital Peptides peptide dosage calculator handles all of these variables dynamically. Input your vial size, diluent volume, body weight, and target dose in mcg/kg, and it returns both the concentration and the precise syringe volume β no unit conversion required.
---Frequently Asked Questions
What is the standard BPC-157 dosage used in research protocols?
The most commonly cited research protocol is 5β10 mcg per kilogram of body weight per day, drawn from published rodent studies. For a 70 kg reference subject, this translates to 350β700 mcg daily. These are preclinical research reference values β not clinical dosing guidelines for human use.
How do I convert a BPC-157 mcg dose to a syringe volume?
Divide your desired dose in mcg by the concentration of your reconstituted solution in mcg/mL. For example, if your solution is 2,500 mcg/mL (5 mg vial + 2 mL bacteriostatic water) and you want 500 mcg, you draw 0.20 mL (20 units on a U-100 syringe). Use the peptide calculator to automate this step.
Why is a PDF dosage calculator less reliable than an online calculator?
PDF calculators are static β they pre-populate values for specific vial sizes and reconstitution volumes. If your protocol uses different ratios, every pre-calculated value becomes inaccurate. A dynamic tool adjusts in real time based on your actual inputs, eliminating the most common source of dosing error.
How long is reconstituted BPC-157 stable?
When reconstituted with bacteriostatic water and stored at 2β8Β°C (36β46Β°F), BPC-157 solution is generally considered stable for 7β10 days. Do not freeze reconstituted solutions, as repeated freeze-thaw cycles degrade peptide integrity.
Is BPC-157 legal to purchase for research in the United States?
As of 2026, BPC-157 occupies a gray regulatory area in the United States. It is not FDA-approved for human use and is not a scheduled controlled substance, but it is also not approved for compounding. Regulatory discussions about potential compounding pathways were ongoing in early 2026. Researchers should verify current local regulations before procurement. It is prohibited by WADA under the S0 category.
References
- Sikiric P, Seiwerth S, Rucman R, et al. (2015). "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Current Pharmaceutical Design, 21(25), 3606β3616. Demonstrated systemic and GI protective effects of BPC-157 in rodent models at 10 mcg/kg. PubMed
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. (2011). "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." Journal of Applied Physiology, 110(3), 774β780. Showed accelerated tendon repair and fibroblast upregulation with BPC-157 in vitro and in vivo. PubMed
- Sikiric P, Hahm KB, Blagaic AB, et al. (2020). "Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response." Biomedicines, 8(10), 407. Reviewed angiogenic and NO-mediated mechanisms underlying BPC-157 tissue protection. PubMed
- Gwyer D, Wragg NM, Wilson SL. (2019). "Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing." Cell and Tissue Research, 377(2), 153β159. Meta-analysis of tendon, ligament, and muscle healing outcomes in BPC-157 rodent studies. PubMed
- World Anti-Doping Agency (WADA). (2026). "Prohibited List β S0: Non-Approved Substances." Confirms BPC-157 is prohibited in-competition and out-of-competition under the S0 category. WADA Prohibited List